Today’s News Headlines
GLP-1s keep making headlines—but the bigger story may be what happens when people stop them. New research continues to show that weight regain after discontinuation is common, which reinforces a core obesity-medicine message: these medications can be powerful tools, but they work best as part of a long-term plan, not a short-term sprint.
(pubmed.ncbi.nlm.nih.gov)
Today’s Top Stories
1) Stopping GLP-1s often leads to weight regain
A recent systematic review concluded that discontinuing GLP-1 receptor agonists is associated with weight regain, even when lifestyle changes are part of the picture. A large retrospective cohort study published in 2025 also found that many patients lost weight while taking GLP-1s, but rebound after stopping remained a real concern.
Why it matters: If you’re using a GLP-1 for obesity treatment, maintenance planning matters as much as initial weight loss.
(pubmed.ncbi.nlm.nih.gov)
2) The FDA moved to remove a suicidal ideation warning from GLP-1 labels
In January 2026, the FDA requested removal of suicidal behavior and ideation warnings from GLP-1 receptor agonist medications after reviewing trial data and broader safety evidence. The agency said the labeling update reflects its ongoing safety evaluation, not a claim that mental-health monitoring is unnecessary.
Why it matters: Patients and clinicians still need to take mood changes seriously, but this update may reduce confusion and stigma around these medications.
(fda.gov)
3) New oral obesity-pill data is keeping the pipeline hot
STAT reported that Structure Therapeutics’ obesity pill, aleniglipron, produced about 16% placebo-adjusted weight loss at 44 weeks in a Phase 2 trial. That follows a wave of interest in oral options, including Lilly’s earlier oral GLP-1 candidate data.
Why it matters: The next generation of obesity treatment may be easier to take than injections, but long-term safety, tolerability, and real-world access still need to be proven.
(statnews.com)
Deep Dive: Science Simplified
Why weight loss is easier to start than to maintain
One of the most useful takeaways from recent obesity research is that the body doesn’t treat weight loss like a one-time event. After weight drops, appetite signals, energy expenditure, and food reward can shift in ways that make regain more likely—especially if the plan was built around willpower alone. That’s one reason the best-supported strategies combine nutrition, movement, behavior change, and, when appropriate, medication or surgery.
(pubmed.ncbi.nlm.nih.gov)
A practical myth to bust: “If I regain, it means I failed.” Not true. Regain is common, and the research suggests it often reflects biology, not lack of discipline. The more useful question is: what support would make maintenance more realistic this time?
(pubmed.ncbi.nlm.nih.gov)
3 evidence-based takeaways for readers:
- Aim for a sustainable starting target, not perfection; NIDDK notes that a 5% to 10% loss over about 6 months can already improve health markers.
(niddk.nih.gov) - If you’re on a GLP-1, build maintenance habits early: protein, resistance training, sleep, and a predictable eating routine.
(pubmed.ncbi.nlm.nih.gov) - If a trend promises “effortless” fat loss, be skeptical. Sustainable weight management usually requires structure, not hacks.
(niddk.nih.gov)
Quick Hits
- The FDA is still warning consumers about contaminated weight-loss products and hidden ingredients in supplements sold as “natural” fixes.
(fda.gov) - Cleveland Clinic guidance continues to emphasize that GLP-1 medications commonly cause GI side effects like nausea, constipation, diarrhea, and heartburn.
(health.clevelandclinic.org) - A meta-analysis found that combining lifestyle intervention with GLP-1 therapy improved weight and several cardiometabolic markers more than controls.
(pubmed.ncbi.nlm.nih.gov) - Real-world data continue to show semaglutide 2.4 mg can produce substantial weight loss over a year, though response varies.
(pubmed.ncbi.nlm.nih.gov) - If you’re tempted by a “fat burner,” the evidence remains thin and the safety concerns are real.
(health.clevelandclinic.org) - Recent obesity-pill trial results suggest the oral pipeline is moving fast, but these drugs are not yet a substitute for proven long-term care.
(statnews.com)
By The Numbers
5% to 10%
That’s the initial weight-loss range NIDDK says can meaningfully improve health outcomes for many adults with overweight or obesity. It matters because it reframes success: you do not need dramatic transformation to make a real medical difference.
(niddk.nih.gov)
Ask the Community
What’s been the most helpful maintenance habit for you so far: protein, walking, strength training, meal planning, sleep, or something else?
Tomorrow’s Preview
Tomorrow we’ll dig into Medication Monday: what’s changing in GLP-1 access, what side effects are most manageable, and which cost-saving strategies are actually worth trying.